Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Targets. 2010 Apr;14(4):369-85. doi: 10.1517/14728221003652489.

Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.

Author information

  • 1UCL Institute of Neurology, Department of Molecular Neuroscience, Queen Square, London WC1N 3BG, UK.

Abstract

IMPORTANCE OF THE FIELD:

The socioeconomic burden of an aging population has accelerated the urgency of novel therapeutic strategies for neurodegenerative disease. One possible approach is to target mitochondrial dysfunction, which has been implicated in the pathogenesis of numerous neurodegenerative disorders.

AREAS COVERED IN THIS REVIEW:

This review examines the role of mitochondrial defects in aging and neurodegenerative disease, ranging from common diseases such as Alzheimer's and Parkinson's disease to rare familial disorders such as the spinocerebellar ataxias. The review is provided in two parts; in this first part, we discuss the mitochondrial defects that have been most extensively researched: oxidative stress; bioenergetic dysfunction and calcium deregulation.

WHAT THE READER WILL GAIN:

This review provides a comprehensive examination of mitochondrial defects observed in numerous neurodegenerative disorders, discussing therapies that have reached clinical trials and considering potential novel therapeutic strategies to target mitochondrial dysfunction.

TAKE HOME MESSAGE:

This is an important area of clinical research, with several novel therapeutics already in clinical trials and many more in preclinical stages. In part II of this review we will focus on possible novel approaches, looking at mitochondrial defects which have more recently been linked to neurodegeneration.

PMID:
20184395
DOI:
10.1517/14728221003652489
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center